Evommune signs $1.1bn licence deal with Hinova for EVO570
Evommune has secured exclusive rights outside Greater China to develop EVO570 from Hinova Pharmaceuticals in a deal worth up to $1.1bn.
Evommune has secured exclusive rights outside Greater China to develop EVO570 from Hinova Pharmaceuticals in a deal worth up to $1.1bn.